Drug Profile
Dactolisib companion diagnostic - Novartis
Latest Information Update: 07 Mar 2014
Price :
$50
*
At a glance
- Originator Novartis
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 08 Nov 2012 Clinical trials in Breast cancer (diagnosis) in the US and EU (unspecified route)
- 08 Nov 2012 Clinical trials in Prostate cancer (diagnosis) in the US and EU (unspecified route)
- 08 Nov 2012 Preclinical trials in Non-small cell lung cancer (diagnosis) in Switzerland (unspecified route)